Distinguished in Multiple Myeloma

Merav Leiba

Ashdod, D, IL 
Distinguished in Multiple Myeloma
Ashdod, D, IL 
OverviewLocationsClinical Research

Overview

Merav Leiba practices in Ashdod, Israel. Ms. Leiba is rated as a Distinguished expert by MediFind in the treatment of Multiple Myeloma. Her top areas of expertise are Multiple Myeloma, Waldenstrom Macroglobulinemia, Plasmacytoma, Osteolysis Syndrome Recessive, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 55 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 35 articles and participated in 1 clinical trial in the study of Multiple Myeloma.

Gender
Female

Locations

Ashdod, D, Israel
Other Locations
Jerusalem, JM, Israel
Beersheba, D, Israel
Tel Litwinsky, TA 52662, Israel
Tel Aviv, TA, Israel
Ramat Gan, TA, Israel
Ramat Aviv, TA 69978, Israel
Clalit Health Services, M, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8)
A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8)
Enrollment Status: Active_not_recruiting
Publish Date: March 18, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Pomalidomide, Dexamethasone, Bortezomib
Study Phase: Phase 3
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Other, Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

55 Total Publications

CyTOF profiling of bone marrow immune dynamics across myeloma stages.
CyTOF profiling of bone marrow immune dynamics across myeloma stages.
Journal: Oncoimmunology
Published: August 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Leiba's expertise for a condition
ConditionClose
    View All 9 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile